Jump to content

Umbralisib

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Hazarasp (talk | contribs) at 13:54, 25 July 2017 (Fixed typos and added categories). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Umbralisib is an experimental oral PI3K delta inhibitor (previously known as RP5264 and TGR 1202).[1]

It has had clinical studies for Chronic lymphocytic leukemia (CLL).[2][3]

Three year data (including Follicular lymphoma and DLBCL) was announced June 2016.[4]

It is in combination trials for various leukemias and lymphomas, eg Mantle cell lymphoma (MCL).[5][6]

References

  1. ^ "Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies". clinicaltrials.gov.
  2. ^ Novel BTK, PI3K Inhibitors on Horizon for Relapsed CLL. March 2016
  3. ^ Therapy Focus - TG Could Benefit From Zydelig Setback. March 2016
  4. ^ TG Therapeutics Inc.: TG Therapeutics, Inc. Announces First Patient Enrolled in the Registration-Directed UNITY-DLBCL Phase 2b Trial. June 2016
  5. ^ A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
  6. ^ Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL. 2017
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Umbralisib&oldid=792260754"